{
  "abstract": "Background: Eczematous eruption (EE) is a paradoxical adverse event during interleukin-17A (IL-17A) inhibitor therapy for psoriasis and may require modification or discontinuation of biologic therapy. However, evidence guiding its management remains limited.\n\nMethods: We retrospectively reviewed 13 patients with psoriasis who developed EE during IL-17A inhibitor therapy and subsequently received selective Janus kinase 1 inhibitors (JAK1i; upadacitinib, n=11; abrocitinib, n=2).\n\nResults: JAK1i treatment resulted in rapid clinical improvement, with mean Eczema Area and Severity Index (EASI) scores decreasing from 14.7 to 3.0 and pruritus visual analogue scale scores from 9.1 to 2.2 after 4 weeks; all patients showed marked clinical improvement by week 8. During a median follow-up of 68 weeks from JAK1i initiation, subsequent psoriasis treatment was individualized according to disease course, with heterogeneous subsequent treatment strategies across patients.\n\nConclusion: These findings support the potential use of selective JAK1 inhibitors for rapidly controlling IL-17A inhibitor-associated EE, with subsequent psoriasis management individualized according to the clinical course.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Dermatology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China",
    "Ruijin-Yatsen Joint Laboratory, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People’s Republic of China"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 6,
  "authors": [
    {
      "affs": [
        0,
        1
      ],
      "name": "Li Zhang",
      "orcid": "0000-0002-2714-5045"
    },
    {
      "affs": [
        0
      ],
      "name": "Jingwen Wu"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Jie Zheng"
    },
    {
      "affs": [
        0
      ],
      "name": "Lihong Chen"
    },
    {
      "affs": [
        0
      ],
      "name": "Youcong Wang"
    },
    {
      "affs": [
        0
      ],
      "name": "Xia Li"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/7jv65mcftjwb7.bib",
  "cited_by": 0,
  "doi": "10.2147/ptt.s640212",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13733392/",
  "id": "7jv65mcftjwb7",
  "issns": [
    "2230-326X"
  ],
  "landing_url": "https://doi.org/10.2147/ptt.s640212",
  "language": "en",
  "licence": "CC-BY-NC-4.0",
  "licence_label": "CC BY-NC 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Original Research"
    ],
    [
      "openalex",
      "2403|Psoriasis: Treatment and Pathogenesis"
    ]
  ],
  "openalex": "W7224826048",
  "pdf_url": "https://www.dovepress.com/article/download/121636",
  "pmcid": "PMC13733392",
  "pmid": "42985208",
  "published": "2026-10-31",
  "publisher": "Dove Press",
  "ris": "https://research.draconitic.com/paper/7jv65mcftjwb7.ris",
  "sources": [
    {
      "first_seen": "2026-11-08T12:23:10Z",
      "native_id": "PMC13733392",
      "source": "pmc",
      "url": "https://doi.org/10.2147/ptt.s640212"
    }
  ],
  "subjects": [
    {
      "field": "biology",
      "origin": "openalex:2403|Psoriasis: Treatment and Pathogenesis",
      "subfield": "immunology"
    }
  ],
  "title": "JAK1 Inhibitors for Eczematous Eruptions Following Anti-IL-17A Therapy in Psoriasis: A Case Series",
  "title_text": "JAK1 Inhibitors for Eczematous Eruptions Following Anti-IL-17A Therapy in Psoriasis: A Case Series",
  "type": "peer-reviewed",
  "updated_at": "2026-11-08T12:23:10Z",
  "url": "https://research.draconitic.com/paper/7jv65mcftjwb7",
  "venue": "Psoriasis: Targets and Therapy",
  "versions": []
}